Version May 2024
Conjunctivitis and keratitis: Children ≥4 years and Adolescents: Ophthalmic: Instill 1 to 2 drops in each eye 4 to 6 times daily at regular intervals
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely needed due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely needed due to low systemic absorption.
(For additional information see "Cromolyn (sodium cromoglicate) (ophthalmic): Drug information")
Conjunctivitis and keratitis: Ophthalmic: Instill 1 to 2 drops in each eye 4 to 6 times daily. Symptomatic response is often evident within a few days; continue therapy as long as required.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Ocular: Conjunctival injection, dryness around the eye, edema, eye irritation, immediate hypersensitivity reactions, itchy eyes, puffy eyes, styes, rash, watery eyes
Respiratory: Dyspnea
Hypersensitivity to cromolyn or any component of the formulation
Concerns related to adverse effects:
• Irritation: May cause transient burning or stinging upon instillation.
Special populations:
• Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by contact lenses; do not wear contact lenses during treatment.
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only; not for injection. To avoid contamination, do not touch dropper tip to eye, eyelid, fingers, or any other surface when placing drops in eyes.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as sodium:
Generic: 4% (10 mL)
Yes
Solution (Cromolyn Sodium Ophthalmic)
4% (per mL): $3.72
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For ophthalmic use. Wash hands prior to use. Instill into conjunctival sac avoiding contact of bottle tip with skin or eye. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (Ref). Patients should not wear contact lenses during treatment.
For ophthalmic use only. Wash hands prior to use. Instill drops inside the lower eyelid; avoid instilling directly on the cornea. To avoid contamination, do not touch dropper tip to eye, eyelid, fingers, or any other surface. Do not wear contact lenses during treatment.
Store at 15°C to 25°C (59°F to 77°F). Protect from light. Store in original carton.
Treatment of vernal conjunctivitis, vernal keratoconjunctivitis, and vernal keratitis (FDA approved in ages ≥4 years and adults)
None known.
There are no known significant interactions.
Adverse events have not been observed in animal reproduction studies following SubQ administration. Systemic absorption following ophthalmic application is limited (~0.03%).
Mast cell stabilizer that inhibits the in vivo and in vivo release of histamine and slow-reacting substance of anaphylaxis (SRS-A) associated with antigen-mediated reactions.
Onset of action: Response to treatment: May be seen within a few days; treatment for up to 6 weeks is often required
Absorption: ~0.03%
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
